Cargando…

Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma

BACKGROUND: Gliomas account for more than 60 % of all primary central nervous system neoplasms. Low-grade gliomas display a tendency to progress to more malignant phenotypes and the most frequent and malignant gliomas are glioblastomas (GBM). Another type of glioma, oligodendroglioma originates from...

Descripción completa

Detalles Bibliográficos
Autores principales: Gimenez, Marcela, Marie, Suely Kazue Nagahashi, Oba-Shinjo, Sueli, Uno, Miyuki, Izumi, Clarice, Oliveira, João Bosco, Rosa, Jose Cesar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502388/
https://www.ncbi.nlm.nih.gov/pubmed/26108672
http://dx.doi.org/10.1186/s12885-015-1473-9
_version_ 1782381198157283328
author Gimenez, Marcela
Marie, Suely Kazue Nagahashi
Oba-Shinjo, Sueli
Uno, Miyuki
Izumi, Clarice
Oliveira, João Bosco
Rosa, Jose Cesar
author_facet Gimenez, Marcela
Marie, Suely Kazue Nagahashi
Oba-Shinjo, Sueli
Uno, Miyuki
Izumi, Clarice
Oliveira, João Bosco
Rosa, Jose Cesar
author_sort Gimenez, Marcela
collection PubMed
description BACKGROUND: Gliomas account for more than 60 % of all primary central nervous system neoplasms. Low-grade gliomas display a tendency to progress to more malignant phenotypes and the most frequent and malignant gliomas are glioblastomas (GBM). Another type of glioma, oligodendroglioma originates from oligodendrocytes and glial precursor cells and represents 2–5 % of gliomas. The discrimination between these two types of glioma is actually controversial, thus, a molecular distinction is necessary for better diagnosis. METHODS: iTRAQ-based quantitative proteomic analysis was performed on non-neoplastic brain tissue, on astrocytoma grade II, glioblastoma with short and long survival and oligodendrogliomas. RESULTS: We found that expression of nucleophosmin (NPM1), glucose regulated protein 78 kDa (GRP78), nucleolin (NCL) and heat shock protein 90 kDa (HSP90B1) were increased, Raf kinase inhibitor protein (RKIP/PEBP1) was decreased in glioblastoma and they were associated with a network related to tumor progression. Expression level of heat shock protein 27 (HSPB1/HSP27) discriminated glioblastoma presenting short (6 ± 4 months, n = 4) and long survival (43 ± 15 months, n = 4) (p = 0.00045). Expression level of RNA binding protein nova 1 (NOVA1) differentiated low-grade oligodendroglioma and astrocytoma grade II (p = 0.0082). Validation were done by Western blot, qRT-PCR and immunohistochemistry in a larger casuistry. CONCLUSION: Taken together, our quantitative proteomic analysis detected the molecular triad, NPM1, GRP78 and RKIP participating together with NCL and HSP27/HSPB1 in a network related to tumor progression. Additionally, two new important targets were uncovered: NOVA1 useful for diagnostic refinement differentiating astrocytoma from oligodendroglioma, and HSPB1/HSP27, as a predictive factor of poor prognosis for GBM. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1473-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4502388
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45023882015-07-16 Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma Gimenez, Marcela Marie, Suely Kazue Nagahashi Oba-Shinjo, Sueli Uno, Miyuki Izumi, Clarice Oliveira, João Bosco Rosa, Jose Cesar BMC Cancer Research Article BACKGROUND: Gliomas account for more than 60 % of all primary central nervous system neoplasms. Low-grade gliomas display a tendency to progress to more malignant phenotypes and the most frequent and malignant gliomas are glioblastomas (GBM). Another type of glioma, oligodendroglioma originates from oligodendrocytes and glial precursor cells and represents 2–5 % of gliomas. The discrimination between these two types of glioma is actually controversial, thus, a molecular distinction is necessary for better diagnosis. METHODS: iTRAQ-based quantitative proteomic analysis was performed on non-neoplastic brain tissue, on astrocytoma grade II, glioblastoma with short and long survival and oligodendrogliomas. RESULTS: We found that expression of nucleophosmin (NPM1), glucose regulated protein 78 kDa (GRP78), nucleolin (NCL) and heat shock protein 90 kDa (HSP90B1) were increased, Raf kinase inhibitor protein (RKIP/PEBP1) was decreased in glioblastoma and they were associated with a network related to tumor progression. Expression level of heat shock protein 27 (HSPB1/HSP27) discriminated glioblastoma presenting short (6 ± 4 months, n = 4) and long survival (43 ± 15 months, n = 4) (p = 0.00045). Expression level of RNA binding protein nova 1 (NOVA1) differentiated low-grade oligodendroglioma and astrocytoma grade II (p = 0.0082). Validation were done by Western blot, qRT-PCR and immunohistochemistry in a larger casuistry. CONCLUSION: Taken together, our quantitative proteomic analysis detected the molecular triad, NPM1, GRP78 and RKIP participating together with NCL and HSP27/HSPB1 in a network related to tumor progression. Additionally, two new important targets were uncovered: NOVA1 useful for diagnostic refinement differentiating astrocytoma from oligodendroglioma, and HSPB1/HSP27, as a predictive factor of poor prognosis for GBM. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1473-9) contains supplementary material, which is available to authorized users. BioMed Central 2015-06-25 /pmc/articles/PMC4502388/ /pubmed/26108672 http://dx.doi.org/10.1186/s12885-015-1473-9 Text en © Gimenez et al. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Gimenez, Marcela
Marie, Suely Kazue Nagahashi
Oba-Shinjo, Sueli
Uno, Miyuki
Izumi, Clarice
Oliveira, João Bosco
Rosa, Jose Cesar
Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma
title Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma
title_full Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma
title_fullStr Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma
title_full_unstemmed Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma
title_short Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma
title_sort quantitative proteomic analysis shows differentially expressed hspb1 in glioblastoma as a discriminating short from long survival factor and nova1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502388/
https://www.ncbi.nlm.nih.gov/pubmed/26108672
http://dx.doi.org/10.1186/s12885-015-1473-9
work_keys_str_mv AT gimenezmarcela quantitativeproteomicanalysisshowsdifferentiallyexpressedhspb1inglioblastomaasadiscriminatingshortfromlongsurvivalfactorandnova1asadifferentiationfactorbetweenlowgradeastrocytomaandoligodendroglioma
AT mariesuelykazuenagahashi quantitativeproteomicanalysisshowsdifferentiallyexpressedhspb1inglioblastomaasadiscriminatingshortfromlongsurvivalfactorandnova1asadifferentiationfactorbetweenlowgradeastrocytomaandoligodendroglioma
AT obashinjosueli quantitativeproteomicanalysisshowsdifferentiallyexpressedhspb1inglioblastomaasadiscriminatingshortfromlongsurvivalfactorandnova1asadifferentiationfactorbetweenlowgradeastrocytomaandoligodendroglioma
AT unomiyuki quantitativeproteomicanalysisshowsdifferentiallyexpressedhspb1inglioblastomaasadiscriminatingshortfromlongsurvivalfactorandnova1asadifferentiationfactorbetweenlowgradeastrocytomaandoligodendroglioma
AT izumiclarice quantitativeproteomicanalysisshowsdifferentiallyexpressedhspb1inglioblastomaasadiscriminatingshortfromlongsurvivalfactorandnova1asadifferentiationfactorbetweenlowgradeastrocytomaandoligodendroglioma
AT oliveirajoaobosco quantitativeproteomicanalysisshowsdifferentiallyexpressedhspb1inglioblastomaasadiscriminatingshortfromlongsurvivalfactorandnova1asadifferentiationfactorbetweenlowgradeastrocytomaandoligodendroglioma
AT rosajosecesar quantitativeproteomicanalysisshowsdifferentiallyexpressedhspb1inglioblastomaasadiscriminatingshortfromlongsurvivalfactorandnova1asadifferentiationfactorbetweenlowgradeastrocytomaandoligodendroglioma